The anticonvulsant activity of orally administered δ 9-tetrahydrocannabinol (δ 9-THC), δ 8-THC, cannabidiol (CBD) and cannabinol (CBN) was tested in mice utilizing electroshock and chemoshock methods. In doses tested δ 9-THC afforded no protection to mice from chemoshock seizures and was effective against electroshock only in high doses (160–200 mg/kg). CBD and CBN (150–200 mg/kg) were without effect in both tests.
An interaction between cannbinoids was apparent when all three were administered simultaneously (each at 50 mg/kg) because this combination produced a significant reduction in the duration of the hind-limb extensor phase of the electroshock seizures.
The administration of δ 9-THC significantly potentiated the anticonvulsant effectiveness of phenytoin against electroshock seizures and this effect was further potentiated by the concurrent administration of CBD. Whilst the potentiation of phenytoin by δ 9-THC (50 mg/kg) was of the order of 1.5 times, the combination of δ-9THC and CBD (each 50 mg/kg) produced a four-fold potentiation.
Neither within-cannabinoid interaction nor cannabinoid potentiation of phenobarbitone effectiveness could be demonstrated in chemoshock tests.
The mechanism of the cannabinoid facilitation of phenytoin is unknown but it possibly involves activity at central nervous system level rather than being a metabolic interaction. This drug interaction may have potential clinical significance.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Anderson, P. F., Jackson, D. M., Chesher, G. B.: The interaction of δ 9-tetrahydrocannabinol and cannabidiol on intestinal motility in mice. J. Pharm. Pharmacol. 26, 136–137 (1974)
Brown, W. C.: Unpublished observations (1952) cited by Swinyard et al. (1952)
Carlini, E. A., Leite, J. R., Tannhauser, M., Berardi, A. C.: Cannabinol and Cannabis sativa extract protect mice and rats against convulsive agents. J. Pharm. Pharmacol. 25, 664–665 (1973)
Chesher, G. B., Jackson, D. M., Starmer, G. A.: Interaction of cannabis and general anaesthetic agents in mice. Brit. J. Pharmacol. (in press) (1974)
Cohen, G. M., Peterson, D. W., Mannering, G. J.: Interactions of δ 8-tetrahydrocannabinol with the hepatic microsomal drug metabolizing system. Life Sci. 10, 1207–1215 (1971)
Consroe, P. F., Man, D. P.: Effects of δ 9 and δ 8-tetrahydrocannabinol on experimentally induced seizures. Life Sci. 13, 429–439 (1973)
Davis, J. P., Ramsey, H.H.: Antiepileptic action of marihuana-active substances. Fed. Proc. 8, 284–285 (1949)
Dingel, J. V., Miller, K. W., Heath, E. C., Klausner, H. A.: The intracellular localization of δ 9-tetrahydrocannabinol in liver and its effects on drug metabolism in vitro. Biochem. Pharmacol. 22, 949–958 (1973)
Fujimoto, J. M.: Modification of the effects of δ 9-tetrahydrocannabinol by phenobarbital pretreatment in mice. Toxicol. appl. Pharmacol. 23, 623–634 (1972)
Garriott, J. C., Forney, R. B., Hughes, F. W., Richards, A. B.: Pharmacologic properties of some cannabis related compounds. Arch. int. Pharmacodyn. 171, 425–434 (1968)
Gill, E. W., Paton, W. D. M., Pertwee, R. G.: Preliminary experiments on the chemistry and pharmacology of cannabis. Nature (Lond.) 228, 134–136 (1970)
Goodman, L. S., Greival, M. S., Brown, W. C., Swinyard, E. A.: Comparison of maximal seizures evoked by pentylenetetrazol (Metrazol) and electroshock in mice, and their modification by anticonvulsants. J. Pharmacol. exp. Ther. 108, 168–176 (1953)
Krantz, J. C., Berger, H. J., Welch, B. L.: Blockade of (−)trans-δ 9-tetrahydrocannabinol depressant effect by cannabinol in mice. Amer. J. Pharm. 143, 149–152 (1971)
Kubena, R. K., Barry, H.: Interactions of δ 1-tetrahydrocannabinol with barbiturates and amphetamines. J. Pharmacol. exp. Ther. 173, 94–100 (1970)
Litchfield, J. T., Wilcoxon, F.: A simplified method of evaluating dose-effect experiments. J. Pharmacol. exp. Ther. 96, 99–113 (1949)
Loewe, S.: Studies on the pharmacology of marihuana. In: The marihuana problems in the city of New York. Ed. by the Mayor's Committee on Marihuana, pp. 149–212. Lancaster, Pa.: The Jaques Catell Press 1944
Loewe, S., Goodman, L. S.: Anticonvulsant action of marihuana active substances. Fed. Proc. 6, 352 (1947)
O'Shaughnessy, W. B.: On the preparations of the Indian hemp or guna (cannabis indica): the effects on the animal system in health and their utility in the treatment of tetanus and other convulsive disorders. Trans. Med. Physiol. Soc. Bombay, p. 460 (1842)
Paton, W. D. M., Pertwee, R. G.: Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism. Brit. J. Pharmacol. 44, 250–261 (1972)
Reynolds, J. R.: Therapeutical uses and toxic effects of cannabis indica. Lancet 1, 637–638 (1890)
Sofia, R. D., Solomon, T. A., Barry, H.: The anticonvulsant activity of δ 1-tetrahydrocannabinol in mice. Pharmacologist 13, 246 (1971)
Snedecor, G. W., Cochran, W. G.: Statistical methods. Iowa State University Press 1967
Swinyard, E. A.: Laboratory assay of clinically effective antiepileptic drugs. J. Amer, pharm. Ass. 38, 201–204 (1949)
Swinyard, E. A., Brown, W. C., Goodman, L. S.: Comparative assays of antiepileptic drugs in mice and rats. J. Pharmacol. exp. Ther. 106, 319–330 (1952)
Whittle, B. A.: The use of changes in capillary permeability in mice to distinguish between narcotic and non-narcotic analgesics. Brit. J. Pharmacol. 22, 246–253 (1964)
About this article
Cite this article
Chesher, G.B., Jackson, D.M. Anticonvulsant effects of cannabinoids in mice: Drug interactions within cannabinoids and cannabinoid interactions with phenytoin. Psychopharmacologia 37, 255–264 (1974). https://doi.org/10.1007/BF00421539
- δ 9-Tetrahydrocannabinol